Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -1.08 is 25% above its 5-year average of -1.43, near the high end of its 5-year range (-1.65–-1.08).
33.33% above its 12-month average of -1.62.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.24.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 22 comparable quarters.
EARNINGS PER SHARE (EPS)
-1.08
EARNINGS PER SHARE (EPS) AVG TTM
-1.62
EARNINGS PER SHARE (EPS) AVG 3Y
-1.56
EARNINGS PER SHARE (EPS) AVG 5Y
-1.43
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+33.33%
CURRENT VS 3Y AVG
+30.99%
CURRENT VS 5Y AVG
+24.74%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Caribou Biosciences, Inc.
Market Cap
$116.34M
Earnings Per Share (EPS)
-1.08
TTM Avg
-1.62
3Y Avg
-1.56
5Y Avg
-1.43
Market Cap
$114.48M
Earnings Per Share (EPS)
-0.47
TTM Avg
-0.87
3Y Avg
-1.14
5Y Avg
-0.92
Market Cap
$116.80M
Earnings Per Share (EPS)
-4.09
TTM Avg
-2.59
3Y Avg
-6.03
5Y Avg
-6.97
Market Cap
$115.46M
Earnings Per Share (EPS)
-0.89
TTM Avg
-0.91
3Y Avg
-0.79
5Y Avg
-0.74
Market Cap
$117.76M
Earnings Per Share (EPS)
-1.07
TTM Avg
-1.13
3Y Avg
-1.07
5Y Avg
-0.91
Market Cap
$112.69M
Earnings Per Share (EPS)
-1.52
TTM Avg
-3.16
3Y Avg
-3.35
5Y Avg
-6.72
Market Cap
$113.01M
Earnings Per Share (EPS)
-0.33
TTM Avg
-0.41
3Y Avg
-0.34
5Y Avg
-0.29
Market Cap
$112.82M
Earnings Per Share (EPS)
-0.99
TTM Avg
-1.38
3Y Avg
-1.93
5Y Avg
-2.07
Market Cap
$112.05M
Earnings Per Share (EPS)
-3.21
TTM Avg
-1.79
3Y Avg
-1.14
5Y Avg
-1.14
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | $116.34M | -1.08 | -1.62 | -1.56 | -1.43 |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.48M | -0.47 | -0.87 | -1.14 | -0.92 |
| LENZ Therapeutics, Inc. (LENZ)vs › | $116.80M | -4.09 | -2.59 | -6.03 | -6.97 |
| Genelux Corporation (GNLX)vs › | $115.46M | -0.89 | -0.91 | -0.79 | -0.74 |
| Coya Therapeutics, Inc. (COYA)vs › | $117.76M | -1.07 | -1.13 | -1.07 | -0.91 |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $112.69M | -1.52 | -3.16 | -3.35 | -6.72 |
| MaxCyte, Inc. (MXCT)vs › | $113.01M | -0.33 | -0.41 | -0.34 | -0.29 |
| Foghorn Therapeutics Inc. (FHTX)vs › | $112.82M | -0.99 | -1.38 | -1.93 | -2.07 |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $112.05M | -3.21 | -1.79 | -1.14 | -1.14 |
| BGM Group Ltd. (BGM)vs › | $111.14M | N/A | -5.70 | -9.83 | -0.70 |
Trailing EPS (TTM)
$-1.08
Forward EPS (Est.)
$-0.95
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -1.59 |
| 2024-12-31 | -1.65 |
| 2023-12-31 | -1.38 |
| 2022-12-31 | -1.64 |
| 2021-12-31 | -1.11 |
| 2020-12-31 | -1.24 |
| 2019-12-31 | -0.85 |
